ConstipationPhase 2NCT00299975
A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation
A Phase 2 study testing MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose and MaZiRenWan (MZRW) High dose in people with Constipation, run by Hong Kong Baptist University at 1 site in China.
Trial summary
Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Constipation
- What is being tested?
- MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose and MaZiRenWan (MZRW) High dose
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 97 participants
- Where
- 1 siteChina
- Study dates
- Oct 2006to Oct 2007
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical diagnosis of functional constipation with Rome II criteria
- General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale
- Complete spontaneous bowel movement≦2 movements per week
Who cannot join
- Anti-diarrhoeal therapy
- Drug-induced constipation
- Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum
- Medical history of previous abdominal surgery
- Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements
- Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases
Show all 11Show fewer
- History of laxative abuse
- History of allergy to Chinese herbal medicine
- Psychiatric or addictive disorders
- Pregnancy or breast-feeding
- Any other serious diseases
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation
Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the optimal dosage.
Read the detailed description
Functional constipation (FC) is a common complaint in clinical practice, with the estimated prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different extent. It is comparable with western population, which is 15% in North America. By the definition of Rome II criteria, FC comprises a group of functional disorders, which presents as persistent difficult, infrequent or seemingly incomplete defecation.
Constipation is often perceived to be benign, easily treated condition with short-term treatment being relatively straightforward. However, the fact is the management of FC is perplexed as some subjects complain of constipation more than decade. Moreover, chronic constipation can develop into more serious bowel complaints, such as faecal impaction, incontinence and bowel perforations. There is also accumulating evidence shown that constipated subjects have significantly higher anxiety and depression scores and lower quality of life. Therefore, the demand of effective agents to normalize bowel function is extremely large.
Conventional treatment for constipation mainly relies on dietary fibre and laxatives. Although there is no credible evidence that any serious problem is associated with their prolonged use, the treatment of it has been suboptimal. First, a recent systematic review pointed out that there were paucity of trials for many commonly used agents, therefore, their use might not be well validated. Second, many patients with severe constipation do not respond adequately or lose of effectiveness after a short period of time. Third, many patients who intake dietary fibre complain of flatulence, distension, bloating and poor taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives, such as polyethylene glycol, become increasingly popular due to fewer side effects and better taste, however, the prices are much more expensive than other medications. Many constipation sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects seek for coping strategies, such as asking for medical consultations, taking prescribed medicine and seeking for alternative therapy, involving Chinese medicine.
Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions. The CHM used in study is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced Disorders), which can "moisten the intestines, drain heat, promote the movement of qi and unblock the bowel".
It is well known that randomized controlled trial (RCT) is the gold standard to test the efficacy of intervention, thus in this project, we attempt to follow the basic requirements of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal dosage. We believe such study will benefit the advancement of CHM, or even as the foundation of research study in future.
- Conditions
- Constipation
- Being tested
- MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose, MaZiRenWan (MZRW) High dose
- Keywords
- Randomized Controlled Trials, Medicine, Chinese Traditional, Medicine, Herbal, Constipation
- Medical subject headings
- Constipation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MaZiRenWan (MZRW) Low doseDrug
Also called Hemp Seed Pill
Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
MaZiRenWan (MZRW) Median doseDrug
Also called Hemp Seed Pill
Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
MaZiRenWan (MZRW) High doseDrug
Also called Hemp Seed Pill
Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
| Study group | Role | What they receive |
|---|---|---|
| MaZiRenWan (MZRW) Low dose | Experimental | MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks Receives: Drug: MaZiRenWan (MZRW) Low dose |
| MaZiRenWan (MZRW) Median dose | Experimental | MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks Receives: Drug: MaZiRenWan (MZRW) Median dose |
| MaZiRenWan (MZRW) High dose | Experimental | MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks Receives: Drug: MaZiRenWan (MZRW) High dose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Responder for Complete Spontaneous Bowel Movement (CSBM)
Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Measured: Week3-10
Secondary outcomes (15)
Responder for Complete Spontaneous Bowel Movement (CSBM)
Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Measured: Week11-18
Bowel Movement
Measured: Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18)
Complete Spontaneous Bowel Movement (CSBM)
CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Measured: Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18)
Global Symptoms Improvement
Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply "improved" for score 4 to 6, "same" for score 3 or "worse" for score 0 to 2.
Measured: Week6, 10 & 18
Severity of Constipation
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Sensation of Straining
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Incomplete of Evacuation
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Sensation of Bloating
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Sensation of Abdominal Pain/Cramping
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Passing of Gas
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Measured: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Adverse Effects (e.g. Renal and Liver Function Tests)
Measured: pre-treatment & post-treatment
Blood Urea Level
Measured: Pre-treatment(Week2) & Post-treatment(Week10)
Blood Creatinine Level
Measured: Pre-treatment(Week2) & Post-treatment(Week10)
Serum Glutamic Pyruvic Transaminase(SGPT) Level
Measured: Pre-treatment(Week2) & Post-treatment(Week10)
Serum Glutamic Oxaloacetic Transaminase(SGOT) Level
Measured: Pre-treatment(Week2) & Post-treatment(Week10)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2006 (estimated)
- Study startOct 2006
- Primary completionAug 2007
- Study completionOct 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ConstipationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 97 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hong Kong Baptist University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ZhaoXiang Bian, Hong Kong Baptist University
- Investigators
- ZhaoXiang Bian, PhD, Principal investigator, Hong Kong Baptist University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00299975
- Sponsor's protocol ID
- PID-001
- Status last verified
- Apr 2015
- First submitted
- 6 Mar 2006
- Last updated
- 24 Apr 2015
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol. 2011 Jan;106(1):120-9. doi: 10.1038/ajg.2010.305. Epub 2010 Nov 2.
PubMed 21045817
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation
- ClinicalTrials.gov ID
- NCT00299975
- Acronym / sponsor ID
- PID-001
- Conditions
- Constipation
- Keywords
- Randomized Controlled Trials, Medicine, Chinese Traditional, Medicine, Herbal, Constipation
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 97 participants (actual)
- Lead sponsor
- Hong Kong Baptist UniversityUniversity, hospital or other
- Study start
- Oct 2006
- Primary completion
- Aug 2007 (actual)
- Study completion
- Oct 2007 (actual)
- First posted
- 7 Mar 2006 (estimated)
- Results
- Posted 16 Dec 2011
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the optimal dosage.
Detailed description
Functional constipation (FC) is a common complaint in clinical practice, with the estimated prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different extent. It is comparable with western population, which is 15% in North America. By the definition of Rome II criteria, FC comprises a group of functional disorders, which presents as persistent difficult, infrequent or seemingly incomplete defecation.
Constipation is often perceived to be benign, easily treated condition with short-term treatment being relatively straightforward. However, the fact is the management of FC is perplexed as some subjects complain of constipation more than decade. Moreover, chronic constipation can develop into more serious bowel complaints, such as faecal impaction, incontinence and bowel perforations. There is also accumulating evidence shown that constipated subjects have significantly higher anxiety and depression scores and lower quality of life. Therefore, the demand of effective agents to normalize bowel function is extremely large.
Conventional treatment for constipation mainly relies on dietary fibre and laxatives. Although there is no credible evidence that any serious problem is associated with their prolonged use, the treatment of it has been suboptimal. First, a recent systematic review pointed out that there were paucity of trials for many commonly used agents, therefore, their use might not be well validated. Second, many patients with severe constipation do not respond adequately or lose of effectiveness after a short period of time. Third, many patients who intake dietary fibre complain of flatulence, distension, bloating and poor taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives, such as polyethylene glycol, become increasingly popular due to fewer side effects and better taste, however, the prices are much more expensive than other medications. Many constipation sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects seek for coping strategies, such as asking for medical consultations, taking prescribed medicine and seeking for alternative therapy, involving Chinese medicine.
Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions. The CHM used in study is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced Disorders), which can "moisten the intestines, drain heat, promote the movement of qi and unblock the bowel".
It is well known that randomized controlled trial (RCT) is the gold standard to test the efficacy of intervention, thus in this project, we attempt to follow the basic requirements of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal dosage. We believe such study will benefit the advancement of CHM, or even as the foundation of research study in future.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| MaZiRenWan (MZRW) Low dose | Experimental | Drug: MaZiRenWan (MZRW) Low doseMaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks |
| MaZiRenWan (MZRW) Median dose | Experimental | Drug: MaZiRenWan (MZRW) Median doseMaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks |
| MaZiRenWan (MZRW) High dose | Experimental | Drug: MaZiRenWan (MZRW) High doseMaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Clinical diagnosis of functional constipation with Rome II criteria
- General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale
- Complete spontaneous bowel movement≦2 movements per week
Key exclusion criteria (11 listed)
- Anti-diarrhoeal therapy
- Drug-induced constipation
- Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum
- Medical history of previous abdominal surgery
- Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MaZiRenWan (MZRW) Low doseAlso: Hemp Seed PillDissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks | Drug | MaZiRenWan (MZRW) Low dose |
| MaZiRenWan (MZRW) Median doseAlso: Hemp Seed PillDissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks | Drug | MaZiRenWan (MZRW) Median dose |
| MaZiRenWan (MZRW) High doseAlso: Hemp Seed PillDissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks | Drug | MaZiRenWan (MZRW) High dose |
Primary outcome
Responder for Complete Spontaneous Bowel Movement (CSBM)
Time frame: Week3-10
Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
15 secondary outcomes
Responder for Complete Spontaneous Bowel Movement (CSBM)
Time frame: Week11-18
Bowel Movement
Time frame: Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18)
Complete Spontaneous Bowel Movement (CSBM)
Time frame: Baseline(Week1-2), Within treatment(Week3-10) & Within follow-up(Week11-18)
Global Symptoms Improvement
Time frame: Week6, 10 & 18
Severity of Constipation
Time frame: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Sensation of Straining
Time frame: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Incomplete of Evacuation
Time frame: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Sensation of Bloating
Time frame: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Sensation of Abdominal Pain/Cramping
Time frame: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Passing of Gas
Time frame: Baseline(Week2), Within treatment(Week6), End of treatment(Week10) & End of follow-up(Week18)
Adverse Effects (e.g. Renal and Liver Function Tests)
Time frame: pre-treatment & post-treatment
Blood Urea Level
Time frame: Pre-treatment(Week2) & Post-treatment(Week10)
Blood Creatinine Level
Time frame: Pre-treatment(Week2) & Post-treatment(Week10)
Serum Glutamic Pyruvic Transaminase(SGPT) Level
Time frame: Pre-treatment(Week2) & Post-treatment(Week10)
Serum Glutamic Oxaloacetic Transaminase(SGOT) Level
Time frame: Pre-treatment(Week2) & Post-treatment(Week10)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 21045817Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol. 2011 Jan;106(1):120-9. doi: 10.1038/ajg.2010.305. Epub 2010 Nov 2.
- AbstractLink provided by the sponsor.
Related trials for Constipation
Recruiting
Effects of a Prebiotic-Probiotic Combination on Constipation Symptoms and Quality of Life
Constipation, Abdominal Pain
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
Recruiting
Outcome Research in Bowel Irrigation Techniques for the Treatment of Chronic Constipation and/or Faecal Incontinence
Faecal Incontinence, Chronic Constipation
Active, not recruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
Functional Constipation (FC)
Not yet recruiting
Acupuncture Combined With Transcutaneous Electrical Acupoint Stimulation for Constipation-Predominant Irritable Bowel Syndrome With Anxiety State
IBS, Constipation Predominant, Anxiety State
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ZhaoXiang Bian, PhD principal investigator
Hong Kong Baptist University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing MaZiRenWan (MZRW) Low dose, MaZiRenWan (MZRW) Median dose and MaZiRenWan (MZRW) High dose in people with Constipation, run by Hong Kong Baptist University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Dec 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Responder for Complete Spontaneous Bowel Movement (CSBM) (time frame: Week3-10). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00299975, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2015.